From ASH Meeting on Hematologic Malignancies: How would you treat relapsed/refractory myeloma after transplant?

Jesús Berdeja, MD
Director of Myeloma Research at Sarah Cannon Research Institute in Nashville, Tennessee

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the meeting via an audience response system, but we want to know what you would do.

CLINICAL DILEMMA

A 73-year-old man with relapsed multiple myeloma presents for follow-up with new onset bone pain and anemia.

After his diagnosis of ISS stage II, IgA kappa myeloma, he was treated with four cycles of lenalidomide, bortezomib, dexamethasone, and then single autologous hematopoietic cell transplantation. He experienced a very good partial response (VGPR) and then maintenance with lenalidomide for three years. He stopped maintenance due to symptomatic relapse with new del17p.

He then was treated with daratumumab, bortezomib, dexamethasone and achieved a VGPR that lasted 12 months. Now, he has developed symptomatic relapse. The patient has a history of coronary artery disease and hypertension and is using a walker due to new pain and residual grade 2 peripheral neuropathy.

What regimen would you recommend next?

  1. Carfilzomib, dexamethasone
  2. Bortezomib, pomalidomide, dexamethasone
  3. Daratumumab, pomalidomide, dexamethasone
  4. Elotuzumab, pomalidomide, dexamethasone
  5. Other

Let us know how you would respond at ashclinicalnews@hematology.org!

Here’s how audience members responded:

  • Carfilzomib, dexamethasone
  • Bortezomib, pomalidomide, dexamethasone
  • Daratumumab, pomalidomide, dexamethasone
  • Elotuzumab, pomalidomide, dexamethasone
  • Other

Here’s how ASH Clinical News readers responded:

  • Carfilzomib, dexamethasone
  • Bortezomib, pomalidomide, dexamethasone
  • Daratumumab, pomalidomide, dexamethasone
  • Elotuzumab, pomalidomide, dexamethasone
  • Other

Disclaimer: ASH does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this article is solely at your own risk.

SHARE